Journal
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Volume 14, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13223-018-0234-0
Keywords
Anaphylaxis; Classification; Epidemiology; International Classification of Diseases; Rare diseases; World Health Organization
Categories
Funding
- AstraZeneca
- AstraZeneca [ERS-16-11927]
- MEDA Pharma through CHRUM administration
Ask authors/readers for more resources
In contrast to the majority of allergic or hypersensitivity conditions, worldwide anaphylaxis epidemiological data remain sparse with low accuracy, which hampers comparable morbidity statistics. Data can differ widely depending on a number of variables. In the current document we reviewed the forms on which anaphylaxis has been defined and classified; and how it can affect epidemiological data. With regards to the methods used to capture morbidity statistics, we observed the impact of the anaphylaxis coding utilizing the World Health Organization's International Classification of Diseases. As an outcome and depending on the anaphylaxis definition, we extracted the cumulative incidence, which may not reflect the real number of new cases. The new ICD-11 anaphylaxis subsection developments and critical view of morbidity statistics data are discussed in order to reach new perspectives on anaphylaxis epidemiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available